In vitro study demonstrated that silencing of TRPM4 caused p53 reduction and hyperactivation of EMT, PI3K/AKT/mTOR signaling pathway in endometrial carcinoma, suggesting that TRPM4 can be used clinically to predict endometrial carcinoma prognosis and represents a as potential candidates for new therapeutic targets (Li et al., 2020). This evidence concerns the gene TP53 and endometrial carcinoma.